
---
title: '奥赛康：新药ASKC202片获临床试验申请受理通知书'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=8069'
author: 证券时报网
comments: false
date: Sun, 05 Dec 2021 16:39:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=8069'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ002755" style="color: #2f67d1;text-decoration: none;" code="002755" target="_blank">奥赛康</a>(002755)12月5日晚间公告，全资子公司江苏<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ002755" style="color: #2f67d1;text-decoration: none;" code="002755" target="_blank">奥赛康</a>药业有限公司（简称“江苏<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ002755" style="color: #2f67d1;text-decoration: none;" code="002755" target="_blank">奥赛康</a>”）于近日收到国家药品监督管理局下发的ASKC202片新药临床试验申请《受理通知书》。</p>

                  
</div>
            